Highlights from The Liver Meeting 2025
Featured
The Liver Meeting Speaker Series: Advancing Liver Care
Explore expert insights from The Liver Meeting 2025. Topics in this video will include primary biliary cholangitis (PBC) treatment updates, non-transplant cirrhosis management, and quality of life in liver disease.
The Liver Meeting Speaker Series: Transplant & Liver Frontiers
Explore expert insights from The Liver Meeting 2025. Topics in this video will include liver transplantation innovations and challenges and hepatocellular carcinoma (HCC) care pathways.
Seladelpar Had a Positive Impact on Liver Stiffness Over 3 Years
Seladelpar may alter the trajectory of primary biliary cholangitis (PBC) by improving a key marker of disease progression, according to new data from the phase 3 ASSURE study. The interim analysis of the ongoing, open-label clinical trial, presented at The Liver Meeting 2025, in Washington, D.C., showed that patients with PBC treated with seladelpar maintained or improved their liver stiffness measurements over 3 years of treatment.
November 10, 2025
Read moreRelated Articles
Digital Wellness Intervention Improved Mental Health and Quality of Life for Patients with Chronic Liver Disease
Individuals living with chronic liver disease experience fatigue, anxiety, and depression, which diminish their quality of life and increase their risk for frailty. However, mental health issues are often underrecognized and undertreated in this population, partly due to the challenges involved in prescribing pharmacotherapy to individuals with liver dysfunction.
November 10, 2025
Read moreEvolving Goals Reshape the Treatment of Primary Biliary Cholangitis
While the management of primary biliary cholangitis (PBC) has been redefined by therapies that can achieve meaningful improvements in biomarkers of disease progression, personalized care and aspirational goals may take the management of this chronic liver disease to a whole new level. At The Liver Meeting 2025 in Washington, D.C., experts discussed a shift in the paradigm of PBC management marked not only by the evolution of pharmacologic therapies but also by new, patient-centered approaches to treatment.
November 10, 2025
Read moreIndividuals with Primary Biliary Cholangitis Benefit from Statin Therapy
Hyperlipidemia complicates the course of primary biliary cholangitis (PBC) by increasing the burden of cardiovascular and metabolic disease, which may be underrecognized in this population, according to a retrospective analysis presented at The Liver Meeting 2025, in Washington, D.C.
November 10, 2025
Read moreSeladelpar Treatment Improved Overall Health and Quality of Life in Patients with Primary Biliary Cholangitis
An in-depth look at data from the phase 3 RESPONSE trial, presented at The Liver Meeting 2025, in Washington, D.C., showed that patients with primary biliary cholangitis (PBC) treated with seladelpar achieved meaningful improvements in quality of life and reductions in PBC symptoms over 12 months of treatment.
November 11, 2025
Read moreNoninvasive Algorithm May Accurately Predict the Risk of Portal Hypertension Related to Primary Biliary Cholangitis
An algorithm combining liver stiffness and spleen stiffness values can improve risk stratification by predicting liver decompensation in patients with primary biliary cholangitis (PBC), according to a multicenter study presented at The Liver Meeting 2025 in Washington, D.C., hosted by the American Association for the Study of Liver Disease.
November 11, 2025
Read moreRisk of Fractures Associated with Primary Biliary Cholangitis Does Not Decrease with Bisphosphonate Therapy
A series of analyses presented at The Liver Meeting 2025, in Washington, D.C., showed that primary biliary cholangitis (PBC) increases the risk of bone fractures in women older than 65 years, independently of the postmenopausal status, and revealed that this risk is not mitigated by guideline-directed therapy for osteoporosis.
November 11, 2025
Read moreSeladelpar Passes First Real-World Test in the Treatment of Primary Biliary Cholangitis
Real-world data presented at The Liver Meeting 2025 in Washington, D.C. suggest that seladelpar is a safe and effective second-line therapy for patients with primary biliary cholangitis (PBC) who were previously treated with obeticholic acid.
November 11, 2025
Read moreNoninvasive Biomarkers Show Promise for Risk Stratification in Primary Biliary Cholangitis
Risk stratification scores based on noninvasive laboratory tests offer a safe, cost-effective method for predicting disease progression and the risk for complications in patients with primary biliary cholangitis (PBC), according to a series of studies presented at The Liver Meeting 2025 in Washington, D.C.
November 13, 2025
Read moreThe Influence of Cholestatic Liver Disease on Pregnancy Outcomes Is Understudied
Real-world findings from a large national cohort, presented at The Liver Meeting 2025, in Washington, D.C., showed that clinicians could benefit from targeted recommendations that can better guide the management and counseling of women with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) during pregnancy.
November 13, 2025
Read moreSeladelpar Demonstrated Long-Term Efficacy and Safety in the Treatment of Primary Biliary Cholangitis
The latest data from the open-label ASSURE clinical trial, presented at The Liver Meeting 2025, in Washington, D.C., showed that patients with primary biliary cholangitis (PBC) maintained improvements in biochemical markers of cholestasis over 3 years of treatment with seladelpar, which was generally well tolerated.
November 13, 2025
Read more
© 2025 Wolters Kluwer. All right reserved.